Key result
RAAS blockade remains the cornerstone of treatment for diabetic kidney disease, though clinical trials of dual blockade combinations have shown disappointing long-term outcomes.
Why the study?
Does RAAS blockade or dual RAAS blockade improve outcomes in patients with Diabetic Kidney Disease?
Does RAAS blockade or dual RAAS blockade improve outcomes in patients with Diabetic Kidney Disease?
This review highlights that while single RAAS blockade is foundational for treating diabetic kidney disease, dual RAAS blockade has not shown long-term benefits and carries potential risks.
Answers are grounded in this paper and cite their sources.
Supports single-agent RAAS blockade in diabetic kidney disease; leaves dual blockade strategies open for further trials.
Diabetic Kidney Disease (DKD) is the leading cause of chronic kidney disease in developed countries and its prevalence has increased dramatically in the past few decades. These patients are at an increased risk for premature death, cardiovascular disease, and other severe illnesses that result in frequent hospitalizations and increased health-care utilization. Although much progress has been made in slowing the progression of diabetic nephropathy, renal dysfunction and the development of end-stage renal disease remain major concerns in diabetes. Dysregulation of the renin-angiotensin-aldosterone system (RAAS) results in progressive renal damage. RAAS blockade is the cornerstone of treatment of DKD, with proven efficacy in many arenas. The theoretically-attractive option of combining these medications that target different points in the pathway, potentially offering a more complete RAAS blockade, has also been tested in clinical trials, but long-term outcomes were disappointing. This review examines the "state of play" for RAAS blockade in DKD, dual blockade of various combinations, and a perspective on its benefits and potential risks.
No takes yet. Share an insight, caveat, or question.
Lozano-Maneiro et al. (2015) conducted a review in Diabetic Kidney Disease. Renin-Angiotensin-Aldosterone System (RAAS) blockade was evaluated. RAAS blockade remains the cornerstone of treatment for diabetic kidney disease, though clinical trials of dual blockade combinations have shown disappointing long-term outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: